BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen DJ, Leichman L. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J Clin Oncol. 2015;33:1754-1759. [PMID: 25918302 DOI: 10.1200/jco.2014.59.7765] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C, Luo Y, Zhang Z, Zhang Z, Zhang G, Wang F, Che Y, Fang L, Zhang Y, Sun N, He J. Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. Front Cell Dev Biol 2020;8:580005. [PMID: 33392181 DOI: 10.3389/fcell.2020.580005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shiba D, Terayama M, Yamada K, Hagiwara T, Oyama C, Tamura-Nakano M, Igari T, Yokoi C, Soma D, Nohara K, Yamashita S, Dohi T, Kawamura YI. Clinicopathological significance of cystatin A expression in progression of esophageal squamous cell carcinoma. Medicine (Baltimore) 2018;97:e0357. [PMID: 29642180 DOI: 10.1097/MD.0000000000010357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Zhao C, Lin L, Liu J, Liu R, Chen Y, Ge F, Jia R, Jin Y, Wang Y, Xu J. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma. Oncotarget 2016;7:57310-6. [PMID: 28087951 DOI: 10.18632/oncotarget.9809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
4 Xie CY, Hu YH, Ho JW, Han LJ, Yang H, Wen J, Lam KO, Wong IY, Law SY, Chiu KW, Fu JH, Vardhanabhuti V. Using Genomics Feature Selection Method in Radiomics Pipeline Improves Prognostication Performance in Locally Advanced Esophageal Squamous Cell Carcinoma-A Pilot Study. Cancers (Basel) 2021;13:2145. [PMID: 33946826 DOI: 10.3390/cancers13092145] [Reference Citation Analysis]
5 Ekheden I, Ebrahim F, Ólafsdóttir H, Raaschou P, Wettermark B, Henriksson R, Ye W. Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort. Eur J Clin Pharmacol 2020;76:1029-41. [PMID: 32372150 DOI: 10.1007/s00228-020-02883-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018;10:31-9. [PMID: 29375746 DOI: 10.4251/wjgo.v10.i1.31] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Ding D, Song Y, Yao Y, Zhang S. Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer. Oncol Lett 2017;14:2982-90. [PMID: 28928836 DOI: 10.3892/ol.2017.6547] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Meyerhardt JA, Tepper JE, Venook AP. Special Series: Advances in GI Cancer. J Clin Oncol 2015;33:1717-20. [PMID: 25918284 DOI: 10.1200/JCO.2015.60.8661] [Cited by in Crossref: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Zhu Z, Song J, Gu J, Xu B, Sun X, Zhang S. FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma. Front Pharmacol 2021;12:659735. [PMID: 34040525 DOI: 10.3389/fphar.2021.659735] [Reference Citation Analysis]
11 Wu W, Wei N, Shao G, Jiang C, Zhang S, Wang L. circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6. Onco Targets Ther 2019;12:8197-205. [PMID: 31632070 DOI: 10.2147/OTT.S193031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
12 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016;7:284-92. [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Welsch J, Kup PG, Nieder C, Khosrawipour V, Bühler H, Adamietz IA, Fakhrian K. Survival and Symptom Relief after Palliative Radiotherapy for Esophageal Cancer. J Cancer 2016;7:125-30. [PMID: 26819634 DOI: 10.7150/jca.13655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Liu S, Zhen F, Sun N, Chen J, Cao Y, Zhang S, Cheng H, Ge X, Sun X. Apparent diffusion coefficient values detected by diffusion-weighted imaging in the prognosis of patients with locally advanced esophageal squamous cell carcinoma receiving chemoradiation. Onco Targets Ther 2016;9:5791-6. [PMID: 27703377 DOI: 10.2147/OTT.S107466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
15 Wang Y, Cheng J, Xie D, Ding X, Hou H, Chen X, Er P, Zhang F, Zhao L, Yuan Z, Pang Q, Wang P, Qian D. NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc. Cancer Commun (Lond) 2018;38:33. [PMID: 29871674 DOI: 10.1186/s40880-018-0307-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Zhu X, Ko YJ, Berry S, Shah K, Lee E, Chan K. A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Gastric Cancer 2017;20:646-54. [PMID: 27722826 DOI: 10.1007/s10120-016-0656-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
17 Victor CR, Fujiki FK, Takeda FR, Hoff PMG, de Castria TB. Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. J Glob Oncol 2019;5:1-10. [PMID: 31365299 DOI: 10.1200/JGO.19.00103] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhao Y, Wang Y, Shan L, Peng C, Zhang W, Zhao X. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Sci Rep 2021;11:6800. [PMID: 33762694 DOI: 10.1038/s41598-021-86102-8] [Reference Citation Analysis]
19 Valmasoni M, Pierobon ES, Ruol A, De Pasqual CA, Zanchettin G, Moletta L, Salvador R, Costantini M, Merigliano S. Endoscopic Tumor Length Should Be Reincluded in the Esophageal Cancer Staging System: Analyses of 662 Consecutive Patients. PLoS One 2016;11:e0153068. [PMID: 27088503 DOI: 10.1371/journal.pone.0153068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
20 Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, Oguma E, Goto S. Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports. J Med Case Rep 2021;15:191. [PMID: 33827668 DOI: 10.1186/s13256-020-02634-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Berardi G, Antonelli G, Colasanti M, Meniconi R, Guglielmo N, Laurenzi A, Ferretti S, Levi Sandri GB, Spagnoli A, Moschetta G, Schininà V, Antonini M, Marignani M, Ettorre GM. Association of Sarcopenia and Body Composition With Short-term Outcomes After Liver Resection for Malignant Tumors. JAMA Surg 2020;155:e203336. [PMID: 32965483 DOI: 10.1001/jamasurg.2020.3336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
22 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol. 2016;22:1139-1159. [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
23 Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun 2016;7:13019. [PMID: 27698471 DOI: 10.1038/ncomms13019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
24 Yin K, Liu M, Zhang M, Wang F, Fen M, Liu Z, Yuan Y, Gao S, Yang L, Zhang W, Zhang J, Guo B, Xu J, Liang H, Chen X, Guan W. miR-208a-3p suppresses cell apoptosis by targeting PDCD4 in gastric cancer. Oncotarget 2016;7:67321-32. [PMID: 27634902 DOI: 10.18632/oncotarget.12006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
25 Wu K, Yang Y, Liu D, Qi Y, Zhang C, Zhao J, Zhao S. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget 2016;7:44572-82. [PMID: 27323819 DOI: 10.18632/oncotarget.10067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]